Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab

被引：0

作者：

Tovoli, F. ^{[1
,2
]}

Boe, M. ^{[1
]}

Vivaldi, C. ^{[3
]}

Federico, P. ^{[4
]}

Palloni, A. ^{[5
]}

Dalbeni, A. ^{[6
,7
,8
]}

Solda, C. ^{[9
]}

Stefanini, B. ^{[1
]}

Garajova, I. ^{[10
]}

Ielasi, L. ^{[11
]}

De Lorenzo, S. ^{[12
]}

Granito, A. ^{[1
,2
]}

Stefanini, B. ^{[1
]}

Masi, G. ^{[3
]}

Lonardi, S. ^{[4
]}

Brandi, G. ^{[1
,5
]}

Daniele, B. ^{[4
]}

Auriemma, A. ^{[7
,13
]}

Lani, L. ^{[1
,14
]}

Svegliati-Baroni, G. ^{[15
]}

Campani, C. ^{[16
]}

Piscaglia, F. ^{[1
,2
]}

机构：

[1] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[2] IRCCS Azienda Osped Univ Bologna, Unit Internal Med Hepatobiliary & Immunoallerg Di, Bologna, Italy

[3] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[4] Osped Mare, Med Oncol Unit, Naples, Italy

[5] IRCCS Azienda Osped Univ Bologna, Oncol Unit, Bologna, Italy

[6] Univ Verona, Dept Med, Unit Gen Med C, Verona, Italy

[7] Univ & Hosp Trust AOUI Verona, Verona, Italy

[8] Univ Verona, Liver Unit, Dept Med, Verona, Italy

[9] IRCCS, Veneto Inst Oncol IOV, Oncol Unit 1, Padua, Italy

[10] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[11] Osped Infermi Faenza, Dept Internal Med, Faenza, Italy

[12] Azienda USL Bologna, Oncol Unit, Bologna, Italy

[13] Univ Verona, Sect Innovat Biomed Oncol Area, Dept Engn Innovat Med DIMI, Verona, Italy

[14] IRCCS Azienda Osped Univ Bologna, Unit Semeiot Liver & Alcoholrelated Dis, Bologna, Italy

[15] Polytech Univ Marche, Liver Injury & Transplant Unit, Ancona, Italy

[16] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.139

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

F-34

引用

页码：S79 / S79

页数：1

共 50 条

[1] Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
Tovoli, Francesco
Boe, Maria
Vivaldi, Caterina
Federico, Piera
Palloni, Andrea
Dalbeni, Andrea
Solda, Caterina
Stefanini, Benedetta
Garajova, Ingrid
Ielasi, Luca
De Lorenzo, Stefania
Granito, Alessandro
Stefanini, Bernardo
Masi, Gianluca
Lonardi, Sara
Brandi, Giovanni
Bruno, Daniele
Auriemma, Alessandra
Lani, Lorenzo
Campani, Claudia
Svegliati-Baroni, Gianluca
Piscaglia, Fabio
JOURNAL OF HEPATOLOGY, 2024, 80 : S446 - S446
[2] Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
Tovoli, Francesco
Pallotta, Dante Pio
Vivaldi, Caterina
Campani, Claudia
Federico, Piera
Palloni, Andrea
Dalbeni, Andrea
Solda, Caterina
Lani, Lorenzo
Svegliati-Baroni, Gianluca
Garajova, Ingrid
Ielasi, Luca
De Lorenzo, Stefania
Granito, Alessandro
Stefanini, Bernardo
Masi, Gianluca
Marra, Fabio
Lonardi, Sara
Brandi, Giovanni
Daniele, Bruno
Auriemma, Alessandra
Schiada, Laura
Chen, Rusi
Piscaglia, Fabio
DIGESTIVE AND LIVER DISEASE, 2024, 56 (12) : 2079 - 2084
[3] Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
Lee, Ji Yeon
Lee, Jaejun
Kim, Suho
Yoo, Jae-sung
Kim, Ji Hoon
Yang, Keungmo
Han, Ji Won
Jang, Jeong Won
Choi, Jong Yong
Yoon, Seung Kew
Chun, Ho Jong
Oh, Jung Suk
Sung, Pil Soo
FRONTIERS IN ONCOLOGY, 2024, 14
[4] Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Wu, Meng
Fulgenzi, Claudia A. M.
D'Alessio, Antonio
Cortellini, Alessio
Celsa, Ciro
Manfredi, Giulia F.
Stefanini, Bernardo
Wu, Y. Linda
Huang, Yi-Hsiang
Saeed, Anwaar
Pirozzi, Angelo
Pressiani, Tiziana
Rimassa, Lorenza
Schoenlein, Martin
Schulze, Kornelius
von Felden, Johann
Mohamed, Yehia
Kaseb, Ahmed O.
Vogel, Arndt
Roehlen, Natascha
Silletta, Marianna
Nishida, Naoshi
Kudo, Masatoshi
Vivaldi, Caterina
Balcar, Lorenz
Scheiner, Bernhard
Pinter, Matthias
Singal, Amit G.
Glover, Joshua
Ulahannan, Susanna
Foerster, Fredrich
Weinmann, Arndt
Galle, Peter R.
Parikh, Neehar D.
Hsu, Wei-Fan
Parisi, Alessandro
Chon, Hong Jae
Pinato, David J.
Ang, Celina
JHEP REPORTS, 2025, 7 (02)
[5] Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
Granito, Alessandro
Marinelli, Sara
Terzi, Eleonora
Piscaglia, Fabio
Renzulli, Matteo
Venerandi, Laura
Benevento, Francesca
Bolondi, Luigi
DIGESTIVE AND LIVER DISEASE, 2015, 47 (06) : 518 - 522
[6] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
Mohri, Kunihide
Nagai, Hidenari
Matsuda, Takahisa
Igarashi, Yoshinori
Higai, Koji
ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
[7] Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
Cheon, Jaekyung
Shimose, Shigeo
Kim, Hyung-Don
Niizeki, Takashi
Ryu, Min-Hee
Shirono, Tomotake
Ryoo, Baek-Yeol
Iwamoto, Hideki
Yoo, Changhoon
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (02)
[8] Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma
Miura, Ryoichi
Ono, Atsushi
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Yamaoka, Kenji
Fujii, Yasutoshi
Uchikawa, Shinsuke
Fujino, Hatsue
Nakahara, Takashi
Murakami, Eisuke
Kawaoka, Tomokazu
Miki, Daiki
Tsuge, Masataka
Hayes, C. Nelson
Oka, Shiro
MEDICINE, 2024, 103 (34)
[9] Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
Tomonari, Tetsu
Sato, Yasushi
Tanaka, Hironori
Tanaka, Takahiro
Taniguchi, Tatsuya
Sogabe, Msasahiro
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Takayama, Tetsuji
JGH OPEN, 2020, 4 (06): : 1135 - 1139
[10] Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report
Zhu, Hong
Zhang, Chunyan
Yang, Xi
Yi, Cheng
MEDICINE, 2019, 98 (10)

← 1 2 3 4 5 →